Background: Many genes are involved in non-Hodgkin lymphoma (NHL)-associated translocations regulate the cell cycle, apoptosis, and lymphocyte development. NHL commonly occurs along with molecular genetic abnormalities. Certain molecular genetic abnormalities in NHL are related to specific lymphoma subtypes, which are associated with prognosis or potential therapeutic targets. Aim: This study aimed to screen for the potential expression of key genes in metabolic pathways in lymphoma patients (NHL) in early diagnosed cases and its clinical relevance. Materials and Methods: The relative expression of RNA profiling in 6 early diagnosed NHL patients and 3 healthy control volunteers were determined by using Affymetrix® HTA 2.0 array technology. Results: The total number of screened genes was 67528 around 44,699 coding genes in humans and 22,829 non-coding genes for evidence which has shown fundamental significance in normal development, differentiation, regulation of growth and in human diseases such as cancer. Only 6395 genes were differentially expressed between NHL patients and control. From these genes, 451 genes are up-regulated, and 655 genes were down-regulated. Compared to the control group; NHL patients displayed a significant 1.2 fold increase in the expression of mitochondrial biogenesis genes (POLMRT, TFAM) and ATPAse gene (ATP5D). Whereas a significant decrease was observed in the expression of NADH dehydrogenase genes (NDUFS1, NDUFV2, NDUFA1, NSDYFAB1) and mitochondrial biogenesis genes (TFB2M, UCP2, SLC25A) by 1.5 fold. Additionally, cytochrome oxidase genes (COX5A and COX6A1) exhibited a significant 1.3 fold decrease. This expression alteration is associated with cytogenetic abnormalities and may lead to hematological malignancies. Conclusion: This study explored the importance of certain mitochondrial related genes which can be used as biomarkers for diagnosis and/or prognosis of the disease.